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Abstract
Phospholipase D3 (PLD3) is a protein of unclear function that structurally resembles other
members of the phospholipase D superfamily. A coding variant in this gene confers
increased risk for the development of Alzheimer’s disease (AD), although the magnitude of
this effect has been controversial. Because of the potential significance of this obscure pro-
tein, we undertook a study to observe its distribution in normal human brain and AD-affected
brain, determine whether PLD3 is relevant to memory and cognition in sporadic AD, and to
evaluate its molecular function. In human neuropathological samples, PLD3 was primarily
found within neurons and colocalized with lysosome markers (LAMP2, progranulin, and
cathepsins D and B). This colocalization was also present in AD brain with prominent enrich-
ment on lysosomal accumulations within dystrophic neurites surrounding β-amyloid pla-
ques. This pattern of protein distribution was conserved in mouse brain in wild type and the
5xFAD mouse model of cerebral β-amyloidosis. We discovered PLD3 has phospholipase D
activity in lysosomes. A coding variant in PLD3 reported to confer AD risk significantly
reduced enzymatic activity compared to wild-type PLD3. PLD3 mRNA levels in the human
pre-frontal cortex inversely correlated with β-amyloid pathology severity and rate of cogni-
tive decline in 531 participants enrolled in the Religious Orders Study and Rush Memory
and Aging Project. PLD3 levels across genetically diverse BXD mouse strains and strains
crossed with 5xFAD mice correlated strongly with learning and memory performance in a
fear conditioning task. In summary, this study identified a new functional mammalian phos-
pholipase D isoform which is lysosomal and closely associated with both β-amyloid pathol-
ogy and cognition.
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Author summary
A rare variant in phosphlipase D3 (PLD3) was linked to Alzheimer’s disease (AD) risk,
but both the impact of the variant on protein’s function and the role of PLD3 in sporadic
AD are unknown. Here we show that PLD3 is a lysosomal phospholipase D and that the
AD-associated variant impairs its function. We also discovered that PLD3 expression lev-
els correlate β-amyloid plaque density and the rate of cognitive decline in the longitudinal
Religious Orders Study and Rush Memory and Aging Project. Finally, we observed PLD3
expression levels correlated with memory and learning in a genetically diverse mouse
model. These discoveries establish that PLD3 is an important AD risk gene and implicate
PLD3 in the neurobiology of lysosomal dysfunction in AD.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia and an increasing societal
and economic burden. Multiple gene variants were recently discovered in the Phospholi-
pase D3 (PLD3) gene which conferred increased risk for late onset AD [1]. Phospholipase
D enzymes (PLDs) form a superfamily that are present in viruses, bacteria, and plants all
the way up to mammalian cells. PLDs play an important role in the conversion primarily of
phosphatidylcholine to phosphatidic acid and choline, which has implications for mem-
brane dynamics and cell signaling, among other important cellular processes [2]. The phos-
phodiesterase domains of PLDs contain two highly conserved catalytic regions, HxKxxxxD
motifs (hereafter HKD motif). There are a few non-canonical functions of PLDs which
include nuclease activity and cardiolipase activity, both of which are mediated by substrate
binding at the HKD motif [3,4]. Phospholipase D1 and D2 (PLD1 and PLD2), are con-
firmed to be enzymatically active mammalian PLD isoforms and are druggable proteins
[2,5]. PLD3 was identified as a PLD based upon homology as it contains two HKD motifs,
but two prior studies informally reported that PLD3 lacks PLD activity, although the data
and methodology were not presented [6,7]. The PLD3 gene variants associated with
increased late onset AD risk were initially linked to β-amyloid precursor protein (APP)
processing [1] but this could only be replicated in overexpression conditions [8]. More-
over, a number of subsequent reports failed to replicate the association of the highest
LOAD risk PLD3-V232M coding variant, although this may have been due in part to the
rarity of the coding variant [9–12]. In a later meta-analysis, the PLD3-V232M contributed
to AD risk but had a smaller effect than initially reported, comparable in magnitude to the
apolipoprotein E-ε4 allele [13]. The V232M variant is associated with decreased PLD3
expression and is adjacent to an HKD motif, suggesting PLD3 hypofunction may drive or
modulate AD pathology. Because the molecular function of this protein in the brain is
unclear, it is not known whether this variant affects protein function. Additionally, because
the variant is rare (~1% of affected patients)[1], the relevance of PLD3 to AD processes at a
population level is yet unknown.
In all, there has been little resolution to the controversy whether PLD3 is a legitimate AD-
risk gene, in part due to the limitations of studying rare coding gene variants. In this study, we
aim to address the impact of PLD3 upon AD-related biological and cognitive pathologies
leveraging generalizable population level datasets as well as determining the molecular func-
tion of PLD3.
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Methods
Ethics statement
Tissue procurement was approved by the Vanderbilt University Medical Center Institutional
Review Board and all specimens were de-identified. Written consent for brain donation was
obtained from patients or their surrogate decision makers. Ethical oversight and approval of
animal use was provided by Vanderbilt University Medical Center’s Institutional Animal Care
and Use Committee.
Immunohistochemistry
Human AD brain samples. Formalin fixed brain tissue from sixteen human participants
was obtained from autopsy, including eight cases of autopsy-verified Alzheimer’s disease and
eight neurological controls (Table A in S1 Text). Post-mortem interval was less than 48 hours
for all cases.
Mouse brain samples. WT and 5xFAD 3-month-old mice were euthanized following
ketamine/xylazine anesthesia and transcardial perfusion with ice cold PBS. One hemisphere of
each mouse was used for immunohistochemistry and was drop fixed in ice-cold 4% parafor-
maldehyde/PBS. Brains were left to fix for at least one week at 4˚C before slicing.
Brain sectioning & staining. Fixed brain tissue was sectioned at 50 μM on a Leica vibra-
tome. Sections were then subjected to antigen retrieval, consisting of firstly heating to 95˚C in
citric acid buffer (10 mM citric acid, 0.05% Tween-20, pH 6) for 20 min. Slices were then trans-
ferred to PBS/glycine buffer (100 mM glycine/1x PBS, 0.1% Tween-20) for 10 min shaking at
room temperature, then washed in PBS/0.1% Triton X-100 for 10 min at room temperature.
Sections were then placed in blocking buffer (4% Bovine serum albumin (BSA) in PBS/0.1%
Triton X-100) under a 240-watt LED panel with emission at 390 nm, 430 nm, 460 nm, 630
nm, 660 nm and 850 nm (GrowLight, HTG Supply Inc, USA) for a minimum of 18 hours at
4˚C to reduce autofluorescence related to lipofuscin. Primary antibodies were applied in 4%
BSA in PBS/0.1% Triton X-100 overnight at 4˚ C with gentle shaking (see Table B in S1 Text).
Slices were then washed 3 x 10 min room temperature in PBS/T before application of fluores-
cent secondary antibody in 4% BSA/PBS/T for a minimum of 2 hours room temperature incu-
bation. Slices were finally washed 3 x 10 min room temperature in PBS/T before slide
mounting and coverslipping.
Microscopy. Tissue was visualized on a laser scanning confocal microscope (Zeiss, LSM
710) with a 20x objective or 63x oil immersion objective. Images were acquired with a mini-
mum resolution of at least 1024x1024 pixels. All images underwent routine processing with
the Image J software (https://imagej.nih.gov/ij/download.html). Colocalization was assessed
with Pearson’s correlation coefficient and analyzed with MIPAV image analysis software
(https://mipav.cit.nih.gov/download.php).
AD-BXD studies
AD-BXD mouse line. Mice were generated as previously described [14,15]. Briefly, stable
inbred BXD mouse lines (generating an array of genetic diversity between C57BL/6 and
DBA2/J) were crossed with 5xFAD hemizygous mice, which contain five induced variants
known to cause familial AD in human [16]. Due to the hemizygous nature of 5xFAD, 50% of
the F1 progeny carry the 5xFAD insert (AD-BXD) and 50% are WT for littermate controls
(WT-BXD), where all mice contain the respective BXD line gene diversity. Experiments were
performed at 6 months and 14 months of age upon both male and female mice. Mice under-
went contextual fear conditioning (n = 636), of which a subset was euthanized and brain tissue
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subjected to RNA-Seq (n = 133). Dots represent averaged behavioral performance within BXD
background strain and PLD3 transcript count (n = 100 strains).
Contextual fear conditioning. Following three days of habituation to transport and to
the testing environment, mice were trained on a standard contextual fear conditioning para-
digm as previously described [14,15]. Contextual fear training consisted of a 180 s baseline
period followed by four mild foot shocks (1 s, 0.9 mA), separated by 115±20 s. A 40 s interval
following each foot shock was defined as the post-shock interval, and the percentage of time
spent freezing during each of these intervals was measured using FreezeFrame software (Coul-
bourn Instruments, PA, USA). To calculate an acquisition curve for each strain as an index of
learning, the slope across the average time spent freezing during post-shock intervals 1–4 was
derived. Twenty-four hours later, hippocampus-dependent contextual fear memory (CFM)
was tested by returning the mouse to the testing chamber for 10 min. The percentage of time
spent freezing during the testing trial was measured using FreezeFrame software and used as
an index of CFM.
RNA-Seq. RNA was quantified via RNA-Seq as previously described [14], and available
on GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101144). Briefly, snap fro-
zen hippocampi from AD-BXD strains and non-carrier littermate controls at 6 and 14 months
were used for RNA sequencing. RNA was isolated using the RNeasy mini kit (Qiagen) and
treated with DNase to remove contaminating DNA. Final library pools were sequenced by
75bp paired-end sequencing on a HiSeq2500 (Illumina, San Diego, CA, USA). For final by-
strain analysis, samples belonging to the same strain/sex/age/genotype group were averaged.
ROS-MAP cohort and analysis
Data for human analyses were acquired from two cohort studies acquired and made available
by the Rush University AD center (RADC), all data of which are freely available through the
RADC web portal (www.radc.rush.edu). The Religious Orders Study (ROS) began in 1994 and
the Rush Memory and Aging Project (MAP) began in 1997. Both studies enrolled older adults
without dementia and all participants signed an Anatomical Gift act for brain donation [17–
19]. Written informed consent was obtained from all participants and all protocols were
approved by the Institutional Review Board (IRB). Secondary analyses of data were approved
by the Vanderbilt University Medical Center Institutional Review Board.
Clinical diagnosis. As described in detail previously [20], all clinical and neuropsycholog-
ical data were reviewed by a board-certified neurologist at the time of death and a summary
diagnostic opinion was made blinded to all postmortem data. Consensus diagnosis was
reached in case conference for selected cases.
RNA sequencing. RNA expression levels were obtained, quantified, processed, and nor-
malized previously, and have been described in detail elsewhere [21,22]. Briefly, RNA expres-
sion levels were obtained from frozen, manually dissected sections of dorsolateral prefrontal
cortex. RNA was isolated using the RNeasy lipid tissue kit (Qiagen, Valencia, CA) and was
reverse transcribed and biotin-UTP labeled using the llumina TotalPrep RNA Amplification
Kit from Ambion (Illumina, San Diego, CA, USA). Expression signals were generated using
BeadStudio (Illumina, San Diego, CA, USA). Standard control and normalization methods
were employed to account for technical variability due to differences in hybridization dates.
Reads were aligned using the Bowtie 1 package and then counted using RSEM, as previously
described [22].
Neuropathology. Measures of AD neuropathology were previously quantified and
described in detail elsewhere [17,18,22]. β-amyloid and tau burden were quantified in eight
brain regions using immunohistochemistry including the superior frontal cortex, anterior
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cingulate, hippocampus, angular gyrus, entorhinal cortex, calcarine cortex, middle frontal cor-
tex, and inferior temporal cortex. Neuritic plaques and neurofibrillary tangles were quantified
from silver stained slides, including five brain regions (middle frontal cortex, middle temporal
cortex, inferior parietal cortex, hippocampus, and entorhinal cortex). Each AD neuropathol-
ogy outcome was square-root transformed to better approximate a normal distribution.
In addition, non-AD pathologies were previously quantified and described in detail else-
where [23–29] including TDP-43[30], cerebral amyloid angiopathy (CAA)[25], microscopic
infarcts [24], gross infarcts [28], arteriolosclerosis [26], and atherosclerosis [23]. The quantifi-
cation and modeling of each of these outcomes for the present analytical models has been
described previously [22].
Cognitive outcomes. Cognitive performance was evaluated with 19 neuropsychological
tests as previously described [31]. Tests probed multiple cognitive domains, including seman-
tic memory, working memory, episodic memory, perceptual speed, and perceptual organiza-
tion. Z-scores from all tests were averaged into a single global cognitive composite as
previously described [31].
Statistical analyses. All statistical analyses were performed in R (version 3.5.0; https://
www.r-project.org/). Differential expression of PLD3 across diagnostic groups was assessed
using linear regression with PLD3 entered as a continuous outcome and diagnosis as a categor-
ical predictor with the normal cognition group set as the referent. Linear regression models
assessed the association between PLD3 and neuropathological burden at autopsy with square-
root transformed AD neuropathology traits set as continuous outcomes in separate models. In
all models, covariates included age at death, sex, and postmortem interval.
For cognitive analyses, linear regression models assessed the association between PLD3
expression and cognitive performance at last visit prior to death in the same manner outlined
above. Longitudinal change in cognition was evaluated using mixed-effects regression models
with the intercept and interval (years from death) entered as both fixed and random effects
and included the same covariates as the cross-sectional models. PLD3 associations with longi-
tudinal change were assessed with a PLD3 x interval interaction term in the model.
Cell culture and PLD3 expression
HeLa and NSC34 cells were cultured at 37˚ C and 5% CO2 in DMEM cell media containing
10% fetal bovine serum and penicillin and streptomycin. Cells were plated onto 150 mm cul-
ture flasks and transfected with 20 μg of pCMV3-hPLD3 (HG16349-NH; Sino Biological,
Wayne, PA, USA) utilizing Fugene 6 (Promega, USA) at ~75% confluency. Plasmids contain-
ing hPLD3-V232M and K418R mutations were created using site-directed mutagenesis against
PLD3 (E0552S, New England BioLabs). The sequence of all plasmids was confirmed prior to
use. siRNA against PLD3 (159175867; Integrated DNA Technologies, Coralville, Iowa USA)
was transfected using Oligofectamine (Invitrogen, USA) and control conditions were trans-
fected with a scrambled siRNA. Target specificity of siRNA and efficiency were confirmed by
western blot (Fig A in S1 Text) and we confirmed that reduction of PLD3 did not alter the
level of PLD1 or PLD2 on lysosomes (Fig B in S1 Text). Experiments were performed 48 h
after transfection.
Lysosomal isolation and enzymatic assay
Lysosomes were isolated similarly to procedures previously described [32]. Briefly, cells were
grown to confluence on a 150 mm dish and treated for 2 hours with a colloid suspension of
dextran-coated iron oxide nanoparticles at a concentration of 10mg/mL in DMEM containing
10% fetal bovine serum and penicillin and streptomycin. The cells were then washed three
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times and allowed to rest for at least 2 hours prior to collection. Cells were scraped free in 1
mL cold homogenization buffer consisting of PBS containing a protease inhibitor cocktail.
The material was homogenized with 8 strokes of a tight fitting Dounce homogenizer and was
applied to a column containing 50 mg fine steel filaments which was placed on a strong mag-
net. The cellular material passing through the column was collected and applied to the column
two more times. The column was then washed with 10 mL cold homogenization buffer. The
column was then placed in a microcentrifuge tube and centrifuged at 10,000 g for 10 minutes
yielding the lysosomal fraction. Approximately 1.5–3% of total protein was recovered in this
fraction. The isolation procedure was conducted in less than 1 hour and all steps were per-
formed on ice. Protein concentration was assessed via the Bradford method (Bio-Safe
#1610786, Bio-Rad, USA). Equal protein of intact lysosomes was loaded in replicate onto
96-well plates and then incubated with Amplex Red PLD assay kit, per manufacturer instruc-
tions (#A12219, ThermoFisher Scientific, USA). Cabbage-derived PLD was used as a positive
control (#P8398, Sigma-Aldrich). Samples were incubated at 37˚ C for 1 hour, and read on a
fluorescent plate reader (POLARstar Omega; BMG Labtech, USA) at excitation: 571 nm/emis-
sion: 585 nm.
Western blot
Cells were scraped from 150 mm dishes in 1 mL cold PBS containing 1% Triton X-100 and a
protease inhibitor cocktail. Tissue was homogenized in the same buffer using a 10 strokes of a
Dounce homogenizer. Lysates were rotated end-over-end at 4˚ C for 60 minutes, then centri-
fuged at 10,000 g for 10 minutes to remove crude cellular debris. Protein concentration of the
resulting lysate was determined with a Bradford assay. The lysate was combined with an equal
volume of 2x Laemmelli’s buffer containing beta-mercaptoethanol and heated to 95˚ C for 10
minutes to denature. Equal protein mass was loaded into each lane of a pre-cast 4–15% gradi-
ent acrylamide gel and run at 200 V. Transfer was performed in a semi-dry apparatus (Trans-
Turbo, Bio-Rad, USA). PVDF membrane were then blocked in 4% bovine serum albumin
(BSA) in phosphate buffered saline (PBS) containing 0.1% Tween-20 (PBST) for 60 minutes.
They were then incubated with primary antibodies diluted in 4% BSA in PBST overnight.
Membranes were then washed 3 x 10 min in PBST prior to incubation with secondary anti-
body (diluted in 4% BSA in PBST) for 2 hours. Membranes were washed three times again,
treated with Clarity chemiluminescence reagent (#1705061, Bio-Rad, USA) and developed on
a chemiluminescence imaging system (12003153, ChemiDoc Imaging System, Bio-Rad, USA)
Graphical and statistical methods. All data were graphed and statistically analyzed using
Prism 6.0 (GraphPad, Inc., La Jolla, CA) or R, as noted. In all statistical tests, P value signifi-
cance thresholds were set a priori to α = 0.05. Specific statistical tests to assess main effects and
post-hoc tests as well as N for all groups are provided in the figure legends.
Results
PLD3 is a lysosomal protein and enriched around β-amyloid plaques
While most early reports suggested PLD3 was a neuronal endoplasmic reticulum-localized
protein [33], a few studies suggested it may, at least partially, localize to the lysosome. Most of
these claims were based on studies of overexpression of the protein [34,35]. Because of contra-
dictory reports regarding the subcellular localization of PLD3, we sought to better resolve the
subcellular localization of PLD3 with attention to endogenous context-relevant tissue. In
human brain tissue, PLD3 staining in neuronal cell bodies colocalized highly with Cathepsin B
(Fig 1) (mean Pearson correlation coefficient 0.84±0.07 for neurological controls, 0.86±0.04
for AD) and other lysosomal markers LAMP2 and Cathepsin D (Fig C in S1 Text). In AD, β-
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amyloid plaques are surrounded by enlarged axon segments, termed dystrophic neurites,
which are filled with lysosome-like organelles [35] (Fig 1). PLD3 was enriched and strongly
localized with lysosomal membrane markers in dystrophic neurites around β-amyloid plaques
(Fig 1), although the association with lumenal markers Cathepsin B/D was attenuated com-
pared to cell bodies (Fig 1), consistent with a prior report that lysosomes in dystrophic neurites
are deficient in luminal proteases [36]. These data confirm that even around β-amyloid pla-
ques, PLD3 remains on lysosomes. We found minimal association of PLD3 with arteriolar
CAA; however, dystrophic neurites form around capillaries with CAA and PLD3 was enriched
in these neurites (Fig D in S1 Text). Similarly, in brain tissue from wild-type and 5xFAD mice
PLD3 was strongly colocalized with markers of lysosomes (Pearson coefficient: 0.72±0.22 for
Fig 1. PLD3 is enriched in lysosomes surrounding parenchymal β-amyloid plaques in AD tissue. A. Low magnification images of temporal lobe cortex from
neurological control and AD brain demonstrated a neuronal pattern of staining against PLD3 (green) and consistent accumulation around β-amyloid plaques. B. 40x
magnification images of the same immunohistochemistry show PLD3 is in a punctate staining pattern within neuronal cell bodies and enriched around β-amyloid
plaques. C. Co-staining with lysosomal marker cathepsin B confirmed PLD3 was primarily lysosomal and enriched in dystrophic neurites in AD brain. D. In 5xFAD
mice, PLD3 was similarly enriched around every β-amyloid plaque and strongly colocalized with LAMP2. E. 40x magnification of WT and 5xFAD tissue demonstrated
strong co-localization of PLD3 with lysosomal membrane marker LAMP2 (Pearson coefficient: 0.84±0.07 for WT, 0.86±0.04 for 5xFAD) and strong staining in
dystrophic neurites around β-amyloid plaques, which are stained blue with methoxy-X04. F. The lysosomal lumenal protease cathepsin B is similarly co-localized with
PLD3 in both normal and diseased neurons.
https://doi.org/10.1371/journal.pgen.1009406.g001
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WT, 0.65±0.10 for 5xFAD). The AD mouse model 5xFAD recapitulates this phenotype (Fig
1). Furthermore, in 5xFAD PLD3 did not colocalize with β-amyloid (Pearson correlation coef-
ficient 0.13±0.10), but was enriched on lysosome-like organelles within dystrophic neurites
surrounding β-amyloid plaques. Finally, to confirm that PLD3 is a lysosomal protein, lyso-
somes were isolated from non-transfected HeLa cells by magnetic fractionation after “pulse
chase” loading of dextran-coated iron-oxide nanoparticles (Fig E in S1 Text). PLD3 was highly
enriched in the lysosomal fraction and accounted for the vast majority of the PLD3 in the cells
(Fig 2B), confirming that PLD3 is primarily a lysosomal protein.
PLD3 has phospholipase D activity in intact lysosomes
PLD3 is detected as two bands on western blot; the lower is reportedly derived from proteolytic
cleavage of the transmembrane domain.[6] Consistent with this report, we found the higher
molecular weight band segregated to the membrane fraction of human brain lysates (Fig F in
S1 Text). We could detect no phospholipase D activity above baseline in total lysate of PLD3
transfected mammalian cells (Fig 2A). We suspected this was due to PLD3 constituting a small
fraction of the total cellular PLD activity, as PLD1 and PLD2 are present as well. Consequently,
we isolated lysosomes from PLD3-transfected NSC34 cells (a murine neuroblastoma line) to
Fig 2. PLD3 has phospholipase D activity in isolated lysosomes. A. Overexpression of PLD3 does not produce increased phospholipase D activity in total lysate of
NSC cells compared to untransfected NSC total lysate. N = 4 biological/assay replicates. B. Lysosomes isolated following transfection of PLD3 via iron dextran
nanoparticles and magnetic affinity columns display enrichment for lysosomal marker LAMP2 and expected lack of cytoskeletal marker tubulin. Lysosomal fraction is
enriched with PLD3, further indicating that PLD3 is a lysosomal protein. C. Lysosomal fractionation demonstrates that overexpressed wild-type PLD3 (P) is
appropriately trafficked to the lysosomal fraction. Similarly, introduction of the AD-associated PLD3 mutation V232M (V) or a mutation in the HKD domain, K418R
(K), did not impact routing to the lysosome (representative blot shown), indicated by Western Blot. Samples isolated via lysosomal isolation detailed in the Methods
section. D. Data derived from lysosomes isolated from transfected NSC cells, each condition containing n = 4 biological/assay replicates per condition and n>16 sample
replicates per condition. Phospholipase D (PLD) activity measured by the Amplex Red PLD assay with negative (control lysosomes) and positive (cabbage PLD) controls
in each assay run. Lysosomes expressing PLD3 display significant increase in PLD activity compared to control lysosomes, which is similar in magnitude to the PLD
activity seen with purified cabbage PLD. Upon cotransfection of siRNA against PLD3 alongside PLD3 transfection, these lysosomes display no PLD activity above the
control condition. PLD3-K418R transfected lysosomes, which contain a mutated lysine residue in its putative HKD domain, have significantly reduced PLD activity
compared to wild-type PLD3 transfected lysosomes. Furthermore, human AD-risk associated variant PLD3-V232M displays no significant PLD activity, and displays a
significant reduction in PLD activity compared to PLD3. Data represented as mean +/- SEM. Data analyzed via one-way ANOVA. ����p<0.0001 following Bonferroni
post-hoc tests.
https://doi.org/10.1371/journal.pgen.1009406.g002
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assess PLD activity, we found that PLD3 containing lysosomes had significantly increased
phospholipase D activity compared to non-transfected lysosomes (Fig 2D). Importantly, over-
expressed PLD3 continued to localize to the lysosome (Fig B in S1 Text). The specificity of the
increase in PLD activity was evaluated by co-transfecting a validated siRNA against hPLD3
(validated in Fig A in S1 Text). Co-transfection with anti-PLD3 siRNA reduced the phospholi-
pase D activity to that of lysosomes transfected with a scrambled siRNA (Fig 2D). The specific-
ity of PLD3 activity via siRNA knockdown was replicated in a human cell line (Fig G in S1
Text). To further confirm that the phospholipase D activity originated from the conserved
HKD domain, we introduced a mutation in the second HKD domain, K418R, which
completely ablated the enzymatic activity of PLD3 (Fig 2D, source data in S1 Data). A plasmid
containing a K203R mutation in the first HKD domain did not efficiently express full length
modified protein. Finally, we found the human AD-associated V232M variant lacked PLD
activity (Fig 2D). PLD3-V232M and PLD3-K203R continued to be trafficked to lysosomes
(Fig 2C). Additionally, PLD3 transfection did not alter PLD1 or PLD2 levels in the lysosome
(Fig B in S1 Text), which are known to be functional PLD enzymes. These data suggest PLD3
is a functional phosopholipase D in lysosomes.
Variance in human PLD3 mRNA levels correlated with β-amyloid
deposition and cognition in aged and AD participants
We evaluated whether stratifications in human PLD3 gene expression in the brain correlate
with AD risk. The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP)
enrolled older adults without dementia who agreed to annual clinical evaluations and brain
donation [17–19]. A total of 531 ROS/MAP participants had mRNA expression levels mea-
sured from frozen sections of dorsolateral prefrontal cortex, as previously described [21],
along with autopsy measures of neuropathology and premorbid longitudinal neuropsychologi-
cal test performance. Participants were well educated, predominantly female, predominantly
non-Hispanic white, and on average 89 (±7) years of age at death.
In linear regression models covarying for age at death, sex, and postmortem interval, higher
prefrontal cortex expression of PLD3 was associated with lower β-amyloid plaque burden mea-
sured via immunolabeling, explaining 3% of the variance beyond covariates (Fig 3A; PLD3: β
= -0.004, p = 1.7x10-6). β-amyloid plaque burden remained significantly associated when
covarying for clinical diagnosis (p = 1.6x10-5). Similarly, higher prefrontal cortex expression of
PLD3 was associated with neurofibrillary tangle burden quantified by silver stain (β = -0.0006:
p = 0.03) and IHC (β = -0.002, p = 0.03), however in both tangle models, inclusion of in vivo
clinical diagnosis attenuated PLD3 associations (p>0.07). When covarying for age at death,
sex, and pos t mortem interval, lower levels of PLD3 were observed among AD cases compared
to cognitively normal participants (β = -11.9, p = 0.03). PLD3 levels were not associated with
cerebral atherosclerosis (Fig H in S1 Text). In cognitive analyses, high prefrontal cortex
expression of PLD3 was associated with a slower rate of global cognitive decline when adjust-
ing for age at death, sex, postmortem interval, and the interval between the final neuropsycho-
logical assessment and death (β = 0.0002, p = 0.02) (Fig 3D).
We observed a subtle sex difference in PLD3 associations. Prefrontal cortex levels of PLD3
interacted with sex on β-amyloid plaque density measured with IHC (β = 0.004, p = 0.02) (Fig
3B) and on cross-sectional global cognitive performance at the final visit before death (β =
-0.004, p = 0.03). In both cases, PLD3 associations were stronger in female than male partici-
pants. When performing sensitivity analyses for cell type fraction leveraging the abundance of
cell-specific single gene markers (e.g., ENO2 for neurons, GFAP for astrocytes, CD68 for micro-
glia), PLD3 associations with β-amyloid and cognitive decline remained significant (p<0.05).
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PLD3 mRNA levels are lower in AD-BXD mice and correlated with
learning and memory performance
The BXD mouse model was created by crossing a wild-type mouse with C57BL/6J background
with a DBA/2J mouse to produce a family of inbred sub-strains that capture a range of genetic
Fig 3. PLD3 expression correlates with neuropathology and cognitive trajectory. Human hippocampal PLD3 mRNA counts (in transcripts per million, TPM) were
obtained from the ROS/MAP cohort A. Regression analysis reveals across all clinical diagnoses, higher levels of PLD3 appear protective with respect to lower β-amyloid
plaque counts in prefrontal cortex. B. Protective effect of PLD3 expression on β-amyloid burden is stronger in women. C. Across all clinical diagnoses, higher levels of
PLD3 correlate with slower rates of cognitive decline. D. PLD3 expression correlates with memory function.
https://doi.org/10.1371/journal.pgen.1009406.g003
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diversity. AD-BXD mice were produced by crossing the resulting BXD strains with 5xFAD
hemizygotes, an animal model containing five pro-β-amyloidosis mutations [14] (Fig 4A).
PLD3 mRNA levels were significantly lower in AD-BXD mice than their wild type BXD coun-
terparts (Fig 4B). Mice were subjected to a modified contextual fear memory test (as previ-
ously described [13]) due to its well-validated sensitivity to discern learning and memory
impairments in multiple AD mouse models [37,38]. On the first experimental day, freezing
behavior was measured following repeated mild foot-shocks to assess learning acquisition
rates and the second day freezing behavior in the same environmental context without the pre-
sentation of foot-shocks was measured for analysis of memory recall. Following behavioral
experimentation at the respective time points, a WT and 5xFAD mouse from each strain was
euthanized to analyze mRNA levels in hippocampus via RNA-Seq. We modeled strain-aver-
aged behavioral performance against PLD3 mRNA transcript counts and found that PLD3 lev-
els (adjusting for age and sex) predicted learning acquisition slope (β = 0.06, p = 2.8x10-6,
explaining 6% of the variance) (Fig 4D, 4F and 4H). When adjusting for age and sex, PLD3
levels were a significant predictor of fear memory recall (β = 0.09, p = 0.03) (Fig 4C, 4E, and
4G). When including genotype and BXD background strain, PLD3 remained predictive of
learning acquisition speed (β = 0.04, p = 0.003) but not when modeling fear memory recall (β
= 0.085, p = 0.08). These findings are unsurprising as the main effect for the AD-BXD behav-
ioral stratification was observed upon learning acquisition slope rather than memory recall, as
recall is more strongly sensitive to β-amyloid burden [14,15]. Collectively, these human and
animal data suggest that PLD3 expression is linked to cognition in the aged brain. Of note per-
taining to the reports of motor deficits with PLD3 hypofunction [6], PLD3 levels were not pre-
dictive of narrow beam balance in the BxD cohort (Fig I in S1 Text).
Discussion
Rare PLD3 coding gene variants conferring an increased risk of late onset AD were discovered
in 2014 but have remained controversial in large part due to the unknown function of PLD3
and unclear molecular impact of the rare variant [1]. Here, we leveraged multimodal datasets
that reflect the role of PLD3 at a population level in both a large, longitudinal human study
and in a genetically diverse murine model to establish a functional connection between PLD3
expression and AD-related cognitive impairment. In humans, we found a protective associa-
tion between increased PLD3 expression and β-amyloid plaque burden. Increased PLD3
expression correlated with reduced rate of cognitive decline in the ROSMAP cohort (Fig 3)
and learning and memory in the AD-BXD mice (Fig 4). While the minor allele frequency for
the AD-associated PLD3 variant is only around 1% [39], these results advance our understand-
ing of the functional connection between PLD3 expression and cognition to establish that
PLD3 may be relevant to AD at a population level.
Endolysosomal dysfunction has become an important research focus in age-related neuro-
degenerative diseases, as many have been linked to lysosomal genes, including, for example,
progranulin mutations in frontotemporal dementia and glucocerebrocidase 1 mutations in
Parkinson’s disease.[40,41] In AD, dystrophic neurites are a consistent pathological feature of
AD made up of enlarged axon segments around β-amyloid plaques clogged with dysfunctional
lysosomes, but unlike the prior examples where haploinsufficiency of key genes accounts for
the lysosomal defect, the mechanism(s) of lysosomal function in AD are less clear at present
[36,42]. Here, we report PLD3 is highly concentrated in abnormal neuronal lysosomes in
axons surrounding β-amyloid plaques (Fig 1), corroborating earlier reports of PLD3 upregula-
tion around β-amyloid plaques [43] and that PLD3 can be routed to the lysosome [34]. The
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close and consistent association of PLD3 with β-amyloid neuropathology further strengthens
the relevance of PLD3 to AD.
Finally, we evaluated the molecular function of PLD3. Because PLD3 is lysosomal at endog-
enous expression levels, we hypothesized that its activity likely requires an acidic pH or some
other feature(s) of the lysosomal microenvironment. Consistent with initial reports [6,7], we
did not detect a change in phospholipase D activity in total cell lysates after overexpressing
PLD3, which is not surprising given lysosomes account for well under 5% of the total lysate
and several other PLD isoforms are present in the lysate. However, when we isolated lysosomes
from transfected mammalian cell lines, we discovered markedly enhanced PLD activity after
transfecting PLD3, which was ablated when an anti-PLD3 siRNA was co-transfected or a
mutation in the putative active site was introduced. Using this assay, we demonstrated that the
AD-associated PLD3 variant, V232M, lacked PLD activity. This discovery strengthens the case
that PLD3-V232M is a bonafide AD risk gene. Moreover, these results give us confidence that
PLD3 is a mammalian PLD isoform.
An alternative molecular function of PLD3 has been proposed. A recent report argued that
both PLD3 and PLD4 have 5’ exonuclease activity and implicated this activity in the function
of antigen presenting cells in the context of autoimmune diseases [3]. PLD4 variants have been
linked to autoimmune disease, particularly rheumatoid arthritis [44–46], but there is no such
association with PLD3. Moreover, we found PLD3 was nearly exclusively expressed in neurons
in the brain and was essentially absent from microglia. PLD3 knock-out mice have been
reported to have increased lysosomal size in neurons [8], and an alteration in neuronal lyso-
somal membrane dynamics (fission or fusion) is more consistent with PLD activity than with
exonuclease activity. It may ultimately be necessary to decipher the structure of PLD3 in
greater detail than currently available to confirm the primary molecular function. Importantly,
however, whether PLD3 is a PLD or 5’ exonuclease, the HKD domains appear to be enzymati-
cally active which raises the probability that an inactivating mutation in PLD3 is truly patho-
genic. Both PLD1 and PLD2 require various activating factors for in vitro activity (including
protein kinase C, PIP2 or ARL1) [47,48], it is therefore highly likely that PLD3 requires similar
factors which are currently unknown but are presumably present in the lysosomal
microenvironment.
While it is possible that PLD3 enrichment in dystrophic neurites represents a compensatory
cellular response to plaque formation, we hypothesize that PLD3 is functionally inactive in
these sites. While considerable protease immunoreactivity has been observed around β-amy-
loid plaques, lysosomes in dystrophic neurites appear to be functioning sub-optimally based
on our observation that they are deficient in lysosomal proteases [35,38,49] compared to lyso-
somes in neuronal cell bodies (Fig 1 and Fig B in S1 Text). Given this functional defect, it is
reasonable to hypothesize that they might also fail to acidify, and if PLD3 required acidic pH
Fig 4. Variation in PLD3 expression predicts cognition in mice. A-H. The AD-BXD mouse model mimics human genetic diversity
with respect to variation of PLD3 expression and subsequent learning and memory deficits. Mice underwent contextual fear testing
(n = 636), of which a subset was euthanized and brain tissue subjected to RNA-Seq (n = 133). Dots represent averaged behavioral
performance within BXD background strain and PLD3 transcript count. A. Schematic of approach to breeding AD-BXD mice; the AD
mouse model 5xFAD (hemizygous) was crossed with genetically diverse strains from the BXD model [13]. Littermate controls were
generated via this F1 cross due to the hemizygosity of the 5xFAD transgene. B. PLD3 hippocampal mRNA expression (displayed in
normalized transcripts per million (TPM)) is widely stratified across BXD background and is reduced in AD-BXD mice at both 6 and 14
months (two-way ANOVA, �p<0.05 & ����p<0.0001 following Bonferroni post-hoc tests). Gray connecting lines indicate shared sex
and BXD background strain for visual comparison. C-H. Contextual fear conditioning behavioral performance regarding fear memory
recall (C, E, G) and fear learning acquisition speed (D, F, H) plotted against the group averaged PLD3 mRNA transcript count. Pooled
cohort of mice display positive correlation with hippocampal PLD3 mRNA expression and fear memory recall (G) and fear learning
acquisition speed (H), with the correlational slope more strongly affected by age in memory recall (E vs C) and acquisition speed (F vs
D).
https://doi.org/10.1371/journal.pgen.1009406.g004
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to be active, it could be functionally inactive in dystrophic neurites. This highlights the need
for further detailed studies to define the physiology of lysosomes within dystrophic neurites. It
may be possible to interrogate dystrophic neurites ex vivo via organotypic tissue culture [50]
using tissue from the 5xFAD mouse or other AD mouse models. Together, these data warrant
further investigation towards the potential protective effect of enhancing PLD3 activity to dis-
rupt AD pathogenesis.
Supporting information
S1 Text. Table A: Neuropathology subjects’ clinical characteristics. Human AD Brain Tissue
Utilized for Neuropathological Immunohistochemistry. Table B: Antibodies Utilized and
Concentrations Used. Fig A: Endogenous PLD3 was detected in HeLa cells as a pair of bands
on western blot at 55 and 65 kDa. These bands were eliminated by transfection of an siRNA
against the human PLD3 transcript and amplified many fold by transfection of a plasmid con-
taining an untagged PLD3 transcript. Manipulating the level of PLD3 did not alter the level of
APP, confirming a previous report [7]. Fig B: PLD3 transfection does not alter lysosomal level
of PLD1 or PLD2. Fig C: PLD3 is associated with lysosomes in human brain and massively
enriched on abnormal lysosomes in dystrophic neurites. PLD3 closely colocalized with neuro-
nal lysosomes and co-labeled with cathepsin D which is a luminal lysosomal protease, as well
as LAMP2 and progranulin with are components of the lysosomal membrane. PLD3 accumu-
lations around β-amyloid plaques co-label with LAMP2 and progranulin. Lysosomes in dys-
trophic neurites are deficient in cathepsins as has been previously reported in animal models
of Alzheimer’s disease. Fig D: Staining human brain axons (neurofilament in red), β-amyloid
(methoxy-XO4 in blue) and PLD3 (in green) demonstrates that PLD3 is not associated with
cerebral amyloid angiopathy in arterioles. However, it is robustly present in dystrophic neur-
ites around capillaries with cerebral amyloid angiopathy. Fig E: A. HeLa cells stably transfected
with GFP-tagged transcription factor EB (TFEB), a transcription factor central to the initiation
of lysosomal biogenesis, demonstrate cytosolic localization of TFEB in basal conditions. Upon
induction of lysosomal biogenesis, TFEB rapidly translocates to the nucleus. To ensure that
loading of dextran-coated small paramagnetic iron oxide nanoparticles (SPIO) did not induce
lysosomal biogenesis, we demonstrated that 12-hour incubation with the nanoparticles did not
induce TFEB translocation. B. Efficiency and purity of lysosome enrichment of lysosome iso-
late by magnetic chromatography are demonstrated by the enrichment of lysosome markers
LAMP1, LAMP2 and Cathepsin D in the lysosomal fraction, without enrichment of mitochon-
drial marker manganese superoxide dismutase (Mn SOD). Fig F: PLD3 in human superior
temporal gyrus. The higher molecular weight band is detected in the membrane fraction while
the lower molecular weight band is primarily in the soluble fraction. This is consistent with
prior reports that the lower molecular weight PLD3 band is derived from cleavage of the trans-
membrane domain. LAMP2 is associated with the lysosomal membrane while Cathepsin D is
present in both fractions as expected. To isolate the soluble fraction, the supernatant was col-
lected after tissue was homogenized in three volumes of TBS with phosphatase and protease
inhibitors and centrifuged at 100,000g for one hour. The membrane fraction was obtained by
resuspending the pellet in three volumes of TBS with 1% Triton X, rotating end-over-end for 1
hour, the centrifuging at 100,000g for one hour. The resulting supernatant contained the mem-
brane fraction. Fig G: Replication study in HeLa cells reveals that PLD3 has enzymatic PLD
activity in human cell line derived lysosomes. Lysosomes isolated from PLD3 transfected HeLa
cells display significantly increased PLD activity compared to control lysosomes (p<0.0001).
Cotransfection of PLD3 and siRNA against PLD3 significantly reduces lysosomal PLD activity
(p<0.0001), indicating the specificity of the enzymatic activity of PLD3. PLD activity in PLD3
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+siRNA compared to control is not significant (p = 0.48). Fig H: PLD3 mRNA levels do not
correlate with cerebral atherosclerotic disease. Fig I: PLD3 mRNA levels in 5x/BXD and wild-
type BXD mice do not correlate with narrow beam performance. Linear regression reveals the
plotted slope is not statistically non-zero (p>0.1), and this does not change upon covarying for
5xFAD genotype (p = 0.475). TPM = transcripts per million, y-axis in seconds.
(DOCX)
S1 Data. Excel file containing source data for PLD activity in Fig 2.
(XLSX)
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